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Prescription Opioid Use in Patients With and Without Systemic Lupus 
Erythematosus — Michigan Lupus Epidemiology and Surveillance Program, 
2014–2015
Emily C. Somers, PhD1,2,3; Jiha Lee, MD1; Afton L. Hassett, PsyD4; Suzanna M. Zick, ND5; Siobán D. Harlow, PhD6; Charles G. Helmick, MD7; 
Kamil E. Barbour, PhD7; Caroline Gordon, MD8; Chad M. Brummett, MD4; Deeba Minhas, MD1; Amrita Padda, MD1; Lu Wang, PhD9;  
W. Joseph McCune, MD1; Wendy Marder, MD1,3
Rheumatic diseases are a leading cause of chronic, noncancer 
pain. Systemic lupus erythematosus (SLE) is a chronic auto-
immune rheumatic disease characterized by periodic flares 
that can result in irreversible target organ damage, including 
end-stage renal disease. Both intermittent and chronic muscu-
loskeletal pain, as well as fibromyalgia (considered a centralized 
pain disorder due to dysregulation of pain processing in the 
central nervous system), are common in SLE. Opioids are 
generally not indicated for long-term management of mus-
culoskeletal pain or centralized pain (fibromyalgia) because 
of lack of efficacy, safety issues ranging from adverse medical 
effects to overdose, and risk for addiction (1,2). In this study 
of 462 patients with SLE from the population-based Michigan 
Lupus Epidemiology and Surveillance (MILES) Cohort and 
192 frequency-matched persons without SLE, nearly one 
third (31%) of SLE patients were using prescription opioids 
during the study period (2014–2015), compared with 8% 
of persons without SLE (p<0.001). Among the SLE patients 
using opioids, 97 (68%) were using them for >1 year, and 31 
(22%) were concomitantly on two or more opioid medications. 
Among SLE patients, those using the emergency department 
(ED) were approximately twice as likely to use prescription 
opioids (odds ratio [OR]  =  2.1; 95% confidence interval 
[CI] = 1.3–3.6; p = 0.004). In SLE, the combined contribu-
tions of underlying disease and adverse effects of immunosup-
pressive and glucocorticoid therapies already put patients at 
higher risk for some known adverse effects attributed to long-
term opioid use. Addressing the widespread and long-term 
use of opioid therapy in SLE will require strategies aimed at 
preventing opioid initiation, tapering and discontinuation of 
opioids among patients who are not achieving treatment goals 
of reduced pain and increased function, and consideration of 
nonopioid pain management strategies.
The MILES Cohort includes patients with SLE from the 
precursor MILES Surveillance Registry (3), which comprised 
persons with incident and prevalent SLE during 2002–2005. 
Briefly, the Registry source population included residents of 
Wayne and Washtenaw counties in southeastern Michigan, 
a region encompassing Detroit and Ann Arbor (population 
approximately 2.4 million). All MILES Registry patients still 
living in or near this region during the 2014–2015 recruitment 
and enrollment period were eligible for inclusion in the Cohort. 
During this period, 192 persons who did not have SLE were 
recruited from a random sample of households in this region 
and frequency-matched to SLE patients by age, sex, race, 
and county of residence. Males were oversampled among this 
group to attain roughly equivalent numbers of males in both 
groups. Ethics approval was obtained from the Institutional 
Review Boards of the University of Michigan and Michigan 
Department of Health and Human Services; written, informed 
consent was obtained from all participants.
Data were collected through structured interviews conducted 
during February 2014–September 2015. Self-reported data 
included all prescription medications currently being taken 
and duration of use; long-term opioid use was defined as use 
for >1 year. ED use was considered one or more visits to an ED 
within the last 12 months. Patient-reported outcome measures 
included fibromyalgia* (4), pain and physical function,† and 
depression and anxiety.§ Measures specific to patients included 
SLE duration, disease activity (5), and SLE-related damage 
resulting from disease or its treatment (6).
Chi-squared tests or independent two-sample t-tests were 
used for comparisons between groups. Two multivariable logis-
tic regression models were used to evaluate factors associated 
with opioid use in the total study population (patients and non-
patients) and in SLE patients only. In multivariable analyses, 
potential confounders included the following a priori-specified 
covariates: age, sex, race, income, education, unemployment, 
health insurance type, patient-reported measures (ED use, 
fibromyalgia, pain, physical functioning, depression, anxiety; 
and, for SLE patients, illness duration, activity, and damage). 
Stata (version 15.1; StataCorp) was used for analyses.
The study population included 462 SLE patients and 192 
nonpatients. Patients were more often female, unemployed, 
and more frequently reported ED use, fibromyalgia, pain, poor 
* Based on survey criteria for fibromyalgia.
† Based on RAND Medical Outcomes Study Short-Form-Survey instrument 
subscales, with reversed scores so that higher scores represent worse states. 
https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html.
§ Based on National Institutes of Health Patient-Reported Outcomes 
Measurement Information System short forms 8b (depression) and 8a 
(emotional distress-anxiety). http://www.healthmeasures.net/explore-
measurement-systems/promis.
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physical function, depression, and anxiety (Table 1). Overall, 
143 (31%) patients and 15 (8%) nonpatients were currently 
using prescription opioids (p<0.01). Among persons currently 
using prescription opioids, median duration (3 years) and 
interquartile range (IQR) (first and third quartiles) were similar 
among patients and nonpatients (IQR = 1 and 5 years, and 
2 and 3 years, respectively; p = 0.91). Among patients using 
prescription opioids, 97 (68%) were on therapy for >1 year 
(Table 2), and 31 (22%) were using two or more opioid medi-
cations concomitantly.
Within the total study population, the odds of opioid use 
among SLE patients were 3 times higher than for nonpatients 
(OR = 3.4, 95% CI = 1.7–6.6; p <0.001) after accounting for 
demographic, psychosocial, and clinical factors (Table 3). In 
analyses of both the total study population and SLE patients 
only, prescription opioid use was twice as likely among persons 
who had at least one ED visit in the last 12 months (total 
population: OR = 2.2, 95% CI 1.4–3.6), SLE patients only: 
OR = 2.1, 95% CI = 1.3–3.6). Pain and reduced physical 
functioning were also significantly associated with opioid use 
TABLE 1. Sociodemographic characteristics and patient-reported outcomes in patients with systemic lupus erythematosus (SLE) and frequency 
matched persons without SLE — Michigan Lupus Epidemiology and Surveillance (MILES) Program, 2014–2015
Characteristic
No. (%) or mean (SD)
P-value†SLE patients (n = 462) Persons without SLE* (n = 192)
Age (yrs), mean (SD) 53.3 (12.3) 53.6 (14.0) 0.78
Sex§
Female 430 (93.1) 154 (80.2) <0.01
Male 32 (6.9) 38 (19.8)
Race
White 233 (50.4) 107 (55.7) 0.47
Black 208 (45.0) 77 (40.1)
Other/Unspecified 21 (4.5) 8 (4.2)
Income below U.S. median 237 (51.3) 114 (59.4) 0.16
Education level
Less than high school 41 (8.9) 16 (8.3) 0.76
High school diploma/GED 46 (10.0) 26 (13.5)
Some college/Associate degree 201 (43.5) 83 (43.2)
Bachelor’s degree 88 (19.1) 37 (19.3)
Graduate/Professional degree 85 (18.4) 30 (15.6)
Unemployed¶ 176 (38.1) 55 (28.6) 0.02
Insurance
Private/Other 206 (44.6) 96 (50.0) 0.20
Medicaid/Medicare 246 (53.2) 89 (46.4)
Uninsured 10 (2.2) 7 (3.6)
Emergency department use 213 (46.1) 56 (29.2) <0.01
Fibromyalgia 190 (41.1) 25 (13.0) <0.01
Pain score,**,†† mean (SD) 48.2 (27.0) 28.4 (27.8) <0.01
Physical function score,**,†† mean (SD) 43.8 (30.2) 24.7 (27.9) <0.01
Depression score,†† mean (SD) 51.8 (9.9) 49.0 (9.1) <0.01
Anxiety score,†† mean (SD) 52.4 (10.1) 49.5 (9.2) <0.01
Prescription opioid use
Prescription opioid use (current) 143 (31.0) 15 (7.8) <0.01
Duration opioid use (years; median, IQR)§§ 3 (1, 5) 3 (2, 3) 0.91
Concomitant use of ≥2 opioids§§ 31 (21.7) 0 (0) 0.04
SLE-specific measures
SLE duration, years (median, IQR) 19.0 (14.0, 26.0) NA NA
SLE activity score (mean, SD)†† 12.9 (8.1) NA NA
SLE damage score (median, IQR)†† 5.0 (3.0, 8.0) NA NA
Abbreviations: GED = General Educational Development certificate; IQR = interquartile range (25th percentile, 75th percentile); NA = not applicable; SD = standard 
deviation.
 * Persons without SLE were frequency matched by age, sex, race, and county.
 † P-values calculated by Pearson’s chi-squared test (categorical data) or two-sample t-test (continuous data).
 § Males were oversampled in persons without SLE to have roughly equivalent numbers of males in both groups.
 ¶ Considered unemployed if aged <65 years, not working over last 12 months, and not in school.
 ** For both the pain and physical function measures, scores were reversed from their original RAND Medical Outcomes Study 36-item Short-Form-Survey instrument 
values so that higher scores represent worse pain and physical functioning, respectively.
 †† Higher score is worse.
 §§ Among persons with current prescription opioid use.
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TABLE 2. Characteristics of persons reporting current prescription 
opioid use — Michigan Lupus Epidemiology and Surveillance (MILES) 
Program, 2014–2015
Factor
No. (%) of prescription opioid users
SLE patients  
(n = 143)
Nonpatients 
 (n = 15)
Opioid use ≥1 year
Yes 97 (67.8) 12 (80.0)
No 46 (32.2) 3 (20.0)
Age group (yrs)
18–44 36 (25.2) 1 (6.7)
45–64 82 (57.3) 10 (66.7)
≥65 25 (17.5) 4 (26.7)
Sex
Female 135 (94.4) 12 (80.0)
Male 8 (5.6) 3 (20.0)
Race
White 59 (41.3) 6 (40.0)
Black 76 (53.2) 8 (53.3)
Other/unknown 8 (5.6) 1 (6.7)
Income
Income <U.S. median 96 (67.1) 13 (86.7)
Income ≥U.S. median 37 (25.9) 2 (13.3)
Education
Less than high school 22 (15.4) 3 (20.0)
High school diploma/GED 17 (11.9) 5 (33.3)
Some college/Associate degree 76 (53.2) 4 (26.7)
Bachelor’s degree 14 (9.8) 3 (20.0)
Graduate/Professional degree 14 (9.8) 0 (0.0)
Employment
Unemployed 81 (56.6) 9 (60.0)
Employed and/or in school 62 (43.4) 6 (40.0)
Insurance
Private/Other 37 (25.9) 3 (20.0)
Medicaid/Medicare 105 (73.4) 12 (80.0)
None 1 (0.7) 0 (0.0)
Patient-reported outcomes
Emergency department use
Yes (in last 12 months) 96 (67.1) 9 (60.0)
No 45 (31.5) 6 (40.0)
See table footnotes on next column.
Factor
No. (%) of prescription opioid users
SLE patients  
(n = 143)
Nonpatients 
 (n = 15)
Fibromyalgia
Yes 89 (62.2) 10 (66.7)
No 54 (37.8) 5 (33.3)
Pain score*,†
<70 60 (42.0) 6 (40.0)
≥70 83 (58.0) 9 (60.0)
Physical function score*,†
<70 73 (51.1) 12 (80.0)
≥70 70 (49.0) 3 (20.0)
Depression score†,§
<56.2 74 (51.8) 8 (53.3)
≥56.2 67 (46.9) 7 (46.7)
Anxiety score†,§
<62.3 99 (69.2) 13 (86.7)
≥62.3 42 (29.4) 2 (13.3)
SLE-specific measures
SLE duration
<15 yrs 29 (20.3) NA
≥15 yrs 113 (79.0) NA
SLE activity score†
SLAQ <12 37 (25.9) NA
SLAQ ≥12 106 (74.1) NA
SLE damage score†
LDIQ <5 41 (28.7) NA
LDIQ ≥5 102 (71.3) NA
Abbreviations: GED  =  General Educational Development certificate; 
LDIQ = lupus damage index questionnaire; NA = not applicable; SLAQ = systemic 
lupus activity questionnaire; SLE = systemic lupus erythematosus.
* For both the pain and physical function measures, scores were reversed from 
their original RAND Medical Outcomes Study 36-item Short-Form-Survey 
instrument values so that higher scores represent worse pain and physical 
functioning, respectively. Cut-points reflect 2 standard deviations from the mean.
† Higher score is worse.
§ Patient-Reported Outcomes Measurement Information System depression 
and anxiety score cut-points were based on PROsetta Stone mapping to the 
Center for Epidemiologic Studies Depression and Generalized Anxiety Disorder 
7-item scales, respectively.
TABLE 2. (Continued) Characteristics of persons reporting current 
prescription opioid use — Michigan Lupus Epidemiology and 
Surveillance (MILES) Program, 2014–2015
when assessing the total population and SLE patients only; for 
each one standard deviation increase (worsening) in pain and 
physical function scores, the odds of opioid use were approxi-
mately 35% and 12% higher, respectively.
Discussion
In this study documenting the extent of prescription opioid 
use in patients with SLE, nearly one third of SLE patients in 
a well-characterized cohort used prescription opioids during 
2014–2015, compared with 8% of frequency-matched persons 
without SLE. Approximately 70% of the SLE patients taking 
prescription opioids were on opioid therapy for >1 year. The 
higher odds of prescription opioid use among patients persisted 
after accounting for several factors in multivariable models. 
ED use in the last 12 months was associated with opioid use 
in both the total population and among SLE patients.
The widespread and long-term use of prescription opioids 
among this cohort of patients with SLE was striking given 
lack of evidence regarding safety and efficacy of opioids for 
treating chronic pain associated with rheumatic disease (1,7). 
Particularly concerning is that some of the less appreciated 
medical risks associated with long-term opioid use, such as 
myocardial infarction, immunosuppression, and osteoporosis 
(8), are potentially compounded in persons with SLE, whose 
baseline risks for these comorbidities are elevated because of the 
underlying disease and adverse effects of immunosuppressive 
and glucocorticoid therapies. Further, recent preliminary data 
suggest that opioids are associated with increased mortality 
in lupus.¶
¶ https://acrabstracts.org/abstract/opiod-use-and-death-in-chronic-pain-patients-
with-systemic-lupus-erythematosis/.
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TABLE 3. Factors associated with prescription opioid use, based on separate multivariable logistic regression models* for the total study 
population and systemic lupus erythematosus (SLE) patients only — Michigan Lupus Epidemiology and Surveillance (MILES) Program, 
2014–2015
Characteristic
Total study population (n = 654) SLE patients only (n = 462)
Prescription opioid use 
prevalence OR (95% CI) p-value
Prescription opioid use 
prevalence OR (95% CI) p-value
Patient status
Nonpatient 7.8% referent NA NA NA NA
SLE 31.0% 3.36 (1.72–6.57) <0.001 NA NA NA
Age (yrs) NA 1.00 (0.98–1.02) NS NA 0.99 (0.96–1.01) NS
Sex
Male 15.7% referent NA 25.0% referent NA
Female 25.2% 0.80 (0.35–1.86) NS 31.4% 0.78 (0.28–2.17) NS
Race
White 19.1% referent NA 25.3% NA NA
Black 29.5% 1.01 (0.62–1.66) NS 36.5% 1.03 (0.60–1.76) NS
Other/Unknown 31.0% 1.14 (0.35–3.70) NS 38.1% 1.10 (0.30–4.07) NS
Income
>U.S. median 14.6% referent NA 18.7% referent NA
≤U.S. median 31.1% 1.21 (0.68–2.14) NS 40.5% 1.14 (0.62–2.11) NS
Education (yrs) NA 0.93 (0.84–1.02) NS NA 0.92 (0.83–1.02) NS
Employment
Employed and/or in school 16.1% referent NA 21.7% referent NA
Unemployed 39.0% 1.32 (0.82–2.11) NS 46.0% 1.21 (0.72–2.03) NS
Insurance
Private 13.3% referent NA 18.0% referent NA
Medicaid/Medicare 34.9% 1.45 (0.82–2.56) NS 42.7% 1.60 (0.85–3.00) NS
None 5.9% 0.39 (0.03–4.27) NS 10.0% 0.43 (0.04–4.79) NS
Patient-reported outcomes
Emergency department use
No visits 13.4% referent NA 18.3% referent NA
≥1 visit last 12 mos 39.0% 2.22 (1.39–3.55) 0.001 45.1% 2.14 (1.27–3.59) 0.004
Fibromyalgia
No 13.4% referent NA 19.9% referent NA
Yes 46.1% 1.50 (0.89–2.54) NS 46.8% 1.18 (0.64–2.16) NS
Pain score†,§ NA 1.35 (1.19–1.53) <0.001 NA 1.36 (1.18–1.58) <0.001
Physical function score†,§ NA 1.11 (1.00–1.24) 0.047 NA 1.13 (1.00–1.27) 0.042
Depression score§ NA 1.01 (0.97–1.05) NS NA 1.01 (0.97–1.05) NS
Anxiety score§ NA 0.97 (0.94–1.01) NS NA 0.98 (0.94–1.02) NS
SLE-specific measures
SLE duration (years) NA NA NA NA 1.02 (0.99–1.05) NS
Activity (SLAQ score) § NA NA NA NA 1.01 (0.96–1.06) NS
Damage (LDIQ score) § NA NA NA NA 0.98 (0.92–1.05) NS
Abbreviations: CI = confidence interval; LDIQ = lupus damage index questionnaire; NA = not applicable; NS = not significant; OR = odds ratio; SLAQ = systemic lupus 
activity questionnaire; SLE = systemic lupus erythematosus.
* Each multivariable model includes all listed factors (i.e., odds ratios are adjusted for all other variables listed in the table): SLE versus nonpatient status (for total 
population model), age, sex, race, income, education, employment, health insurance, emergency department use, fibromyalgia, pain score, physical function score, 
depression score, and anxiety score. The SLE patient only model also included SLE duration, SLE activity score, and SLE damage score.
† For both the pain and physical function measures, scores were reversed from their original RAND Medical Outcomes Study 36-item Short-Form-Survey instrument 
values so that higher scores represent worse pain and physical functioning, respectively. For the regression models, the (reversed) pain and physical function scores 
were scaled by their standard deviations of 10; therefore, each unit change represents one standard deviation change.
§ Higher score is worse.
Whereas rheumatic diseases are a leading cause of chronic, 
noncancer pain (7), data on opioid use and associated outcomes 
in persons with rheumatic diseases are limited. One recent 
study of Medicare beneficiaries with rheumatoid arthritis 
estimated regular opioid use (three or more filled prescrip-
tions or one or more filled 90-day prescription per calendar 
year) at approximately 40% (9). Together with the findings 
from this analysis, the prevalent use of opioids in at least two 
patient populations with rheumatic diseases supports the need 
for better understanding of prescribing patterns, risk factors 
associated with opioid initiation and long-term continuation, 
and pharmacoepidemiology related to adverse medical effects 
of opioids in these patients. Effective interventions in this 
population will need to couple tailored approaches for tapering 
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and discontinuing opioids when indicated, along with preven-
tion of opioid initiation and consideration of nonopioid pain 
management strategies.
Interventions to address opioid use in patients with rheu-
matic diseases will require a better understanding of pain 
management for patients with these complex, chronic condi-
tions, whose sources of pain might be multiple, persistent, 
and severe, and which must be accurately diagnosed to be 
appropriately treated. Sources of SLE-related pain can include 
active inflammatory disease resulting in peripheral pain (e.g., 
arthritis), damage accrual attributable to the disease or its 
treatment (e.g., steroid-induced osteonecrosis or vertebral 
fractures), or centralized pain disorders, such as fibromyalgia, 
the prevalence of which is higher in patients with SLE than 
in the general population (4).
The findings in this report are subject to at least five limita-
tions. First, prescription data were self-reported, which limited 
the ability to examine sources of opioid prescribing or dos-
ing patterns in more detail and could have been subject to 
underreporting attributable to social desirability bias. Second, 
since the original SLE registry reflected the demographics of 
southeastern Michigan (which is predominantly black and 
white), Asians, Hispanics, and other groups were not well 
represented, and results might not be generalizable to the 
wider SLE population. Third, this report addresses prescrip-
tion opioid use, but information on other potential opioid 
sources is unavailable. Fourth, these data reflect 2014–2015; 
trends in opioid prescribing and usage might have changed 
since then. Finally, the cross-sectional nature of this analysis 
precludes assessing temporal relationships for factors associated 
with prescription opioid use. Strengths of this study include 
starting from a population-based SLE registry, inclusion of 
relatively large numbers of well-defined patients with SLE, 
comparing to age-, sex-, race-, and county-matched persons 
without SLE, and use of validated patient-reported outcome 
measures to assess psychosocial and lupus-specific factors in 
relation to prescription opioid use.
In conclusion, during 2014–2015, one third of patients in a 
SLE cohort in southeastern Michigan were using prescription 
opioids, most for longer than 1 year. Given the risks for opioid 
therapy and the lack of pain efficacy data in SLE, it is important 
that clinicians managing SLE, including providers in EDs, be 
aware of the potential adverse effects of opioid therapy in these 
patients, consider nonopioid pain management strategies, and 
be familiar with guidance for opioid tapering or discontinua-
tion when patients are not achieving treatment goals of reduced 
pain and increased function or when otherwise indicated (2).
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